Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review - Wikidata - awgldk - TriplyDB

Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review

Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review

http://www.wikidata.org/entity/Q28083470

about

Choroidal neovascularization secondary to tubulointerstitial nephritis and uveitis syndrome (TINU) in an adult patient.Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.A novel bispecific molecule delivered by recombinant AAV2 suppresses ocular inflammation and choroidal neovascularization Optical Coherence Tomography Angiography Of Pathological Myopia Sourced and Idiopathic Choroidal Neovascularization With Follow-Up.Designing Fcabs: well-expressed and stable high affinity antigen-binding Fc fragments.

P2860

Q36130185-9C0A6F55-9C7F-4909-8979-9F379E6DF4DD Q36256224-AACB0AFC-3D8B-421F-BDD0-FD24B26ADF33 Q36319263-73EA50C5-F5E6-4622-8DD5-91080FC39EC0 Q37206738-F3D28B59-76CB-4967-82F3-0158034283FE Q47597969-48C28A94-039E-4BA0-8729-DAD88E1286A3

P2860

Anti-VEGF therapies in the treatment of choroidal neovascularisation secondary to non-age-related macular degeneration: a systematic review

http://www.wikidata.org/entity/Q28083470

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@ast

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@en

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@nl

type

label

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@ast

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@en

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@nl

prefLabel

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@ast

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@en

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@nl

P1433

Q28083470-08A44FBD-770C-4032-AC77-2109FF7911BA

P1476

Q28083470-5A091CE5-257B-4194-B41A-B1ED154D79A3

P2093

Q28083470-262981DE-301C-4ECC-AED4-17D11A5FF153

Q28083470-2911FE8D-1751-4157-978E-5BF51F43972D

Q28083470-4D2FBF42-A793-487F-804D-1F872A06E26B

Q28083470-578AADF5-FA3F-4895-813E-DCB2E4936BB8

P275

Q28083470-277EC680-6BE9-4F6D-8689-2254D884BC17

P2860

Q28083470-02E985E8-A95A-4E01-B62E-D572F27386D5

Q28083470-069DAEA6-7462-42E5-8A10-E8EE965D7D5D

Q28083470-0CEBA359-1F4F-49FC-94EC-122BBC07A432

Q28083470-19BD8FAD-6260-4FCD-BB24-110EB51B2B01

Q28083470-2384A5F2-7FC1-4F62-9A04-B8CBF40C17E5

Q28083470-2D08A058-18E8-4C08-8B4E-640AD2B4D4B2

Q28083470-43489486-035C-4924-A6EF-091D0217FF24

Q28083470-48DAEF96-C97D-41DD-9BE9-328286A9DCA1

Q28083470-4A0E2107-BBAA-47E0-8B32-39857BEFE3BD

Q28083470-4B856057-AF0E-4EAD-9286-90A5FC43BCBD

P304

Q28083470-789A564E-1914-400E-8941-9936B7A120BA

P31

Q28083470-794D64BC-4989-45D3-BD36-4BA9DD51C841

Q28083470-B46E1F5E-296C-41C2-A188-CF6073141E7B

Q28083470-C0865695-95A3-435C-B5E7-3BEAFAFEB624

P3181

Q28083470-773075B9-7727-40DA-8B1B-7C09E09A9B5B

P356

Q28083470-DF31DCDE-6F7C-42C0-A5F4-096FFB592140

P407

Q28083470-93AEC749-13E8-48D4-9C89-EE5BA10FB404

P433

Q28083470-1508C664-7D1E-490F-9FD0-ABAFD1217D78

P478

Q28083470-B32CEC4F-06F5-4869-8FF0-EC473E0B2793

P50

Q28083470-37A3E9D3-6075-436C-A8CF-C76077909B3A

P5008

Q28083470-09BBE4CC-8178-4CF5-BE42-72E0A7B54027

P577

Q28083470-21FF7A51-D7E1-42FA-A63B-97A83CF7AFC1

P5875

Q28083470-B52CE151-1B96-4247-A61F-D04A97E12B5D

P698

Q28083470-51B3AB53-5236-442D-9D0D-6B5A34A441AE

P921

Q28083470-15BCB39C-CCF5-474A-83A5-0D1B56298087

Q28083470-D1D371E3-0952-41D0-ADDF-BC232C697E1F

Q28083470-FA854EA8-9714-4AA9-BC10-397E010975F1

P932

Q28083470-AAF42589-E062-4ADD-9078-4F01CBDD263D

P3181

P356

BMJOPEN-2015-007746

P1433

P1476

Anti-VEGF therapies in the tre ...... eneration: a systematic review

@en

P2093

Arabella Stuart

http://www.w3.org/2001/XMLSchema#string

Augustine Pereira

http://www.w3.org/2001/XMLSchema#string

Colin Jones

http://www.w3.org/2001/XMLSchema#string

Susan Duckworth

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Ranibizumab for neovascular age-related macular degeneration

Axial length measurements and fundus changes of the myopic eye. I. The posterior fundus.

[Efficacy of intravitreal injections of ranibizumab compared to visudyne phototherapy in myopic choroidal neovascularization associated with high myopia].

Current treatments in diabetic macular oedema: systematic review and meta-analysis

Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Treatment of choroidal neovascularization due to angioid streaks: a comprehensive review.

Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

P304

e007746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P3181

4932181

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJOPEN-2015-007746

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2015-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

275895380

http://www.w3.org/2001/XMLSchema#string

P698

25941188

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

age related macular degeneration

P932

4420986

http://www.w3.org/2001/XMLSchema#string